anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Midazolam
Trial phase: Phase 4
ATC code: N05CD08
SMILES: Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 41
Group description: Intranasal midazolam with mucosal atomizer device administration will follow the Children's Hospital Colorado (CHCO) established policy 'Intranasal Administration (atomization) of Medications'.

Midazolam: Intranasal midazolam with mucosal atomizer device administration will follow the Children's Hospital Colorado (CHCO) established policy 'Intranasal Administration (atomization) of Medications'. As per standard of care, each patient will receive a standardized dose of 0.4mg/kg (maximum dose of 10mg) of intranasal midazolam with the mucosal atomizer device for all procedures.
Eligibility criteria:
Inclusion Criteria:

Patients ≥2 years of age and <18 years of age, and
Parent/legal guardian age ≥18 years of age to <80 years of age
Patients with an American Society of Anesthesiologists (ASA) Physical Status Classification System level 1, 2, and 3

Patients requiring anxiolysis and mild sedation for minor procedures

Minor procedures will include simple lacerations less than 4 cm
Lumbar punctures
Minor incision
Drainage of abscesses that do not require extensive debridement

Must receive the standard of care dosing for either nitrous oxide or intranasal midazolam.

Nitrous oxide up to 70% nitrous concentration will be allowed
Intranasal Midazolam 0.4mg/kg with a max dose of 10mg

Exclusion Criteria:

Nasal injury, nasal obstruction or significant congestion
Laceration that involves the nose and ears or come into contact with the scavenger device or nitrous oxide tubing
Allergy to benzodiazepines
Benzodiazepine dosing for any reason 24 hours prior to procedure
Excessive Epistaxis
Facial or nasal deformity
Copious mucous
Recent (less than 1 week) tympanic membrane graft or middle ear surgery
Recent bleomycin therapy
Patients known to be pregnant at time of enrollment
Patients with severe behavior problems, personality disorders or other mind-altering conditions as determined by administering provider.

Closed space situations such as:

pneumothorax,
air embolus,
pneumocephalus, or
craniotomy in the last 3 weeks,
intraocular surgery with retained gas,
pulmonary bullae,
severe emphysema, or
bowel obstruction.

Patients with significant co-morbidities:

severe pulmonary disease,
cardiac disease,
hematologic diseases associated with B12 deficiency,
sickle cell disease.
Patients with acute otitis media and/or sinusitis
History of paradoxical reaction to nitrous oxide
Known Methicillin-resistant Staphylococcus aureus (MRSA+) patients
Co-administration of additional sedation or analgesic medications
Intervention: Pituitrin
Trial phase: Phase 2 | Phase 3
SMILES: NC(=O)CCC1NC(=O)C(Cc2ccccc2)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(N)CSSCC(C(=O)N2CCCC2C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC1=O.NCCCCC(NC(=O)C1CCCN1C(=O)C1CSSCC(N)C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(Cc2ccccc2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(N)=O)C(=O)N1)C(=O)NCC(N)=O
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Patients randomized to this arm will receive a continuous arginine vasopressin infusion immediately following the modified ultrafiltration (MUF) period of their cardiac surgery.

Vasopressin, Arginine: Subjects will be started on a blinded continuous infusion of study drug/placebo in the OR, immediately following the completion of the MUF at 0.3 mU/kg/min. All caregivers will be blinded to the arm assignment. The infusion will run for 20 hours, at which time it will be weaned off at 0.1 mU/hr, over 3 hours.During the active study period, the care team will treat subjects per SOC, using any preferred medication to correct low cardiac output; there is no restriction on using open-label vasopressin during the active study treatment period.
Eligibility criteria:
Inclusion Criteria:

Planned completion of Fontan palliation
English or Spanish speaking
Completion of Informed Consent

Exclusion Criteria:

Previous failed attempts at Fontan completion with subsequent takedown
Planned concomitant atrioventricular valvuloplasty or neoaortic valve or arch reconstruction at the time of Fontan completion
History of renal failure requiring renal replacement therapy
Absence of informed consent
Intervention: Ibuprofen
Trial phase: Phase 2
ATC code: C01EB16 | G02CC01 | M01AE01 | M01AE14 | M01AE51 | M02AA13 | N02AJ08 | N02AJ19 | R02AX02
SMILES: CC(C)Cc1ccc(C(C)C(=O)O)cc1
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 90
Group description: Oral Ibuprofen at 10mg/kg dose and placebo of equal volume

Ibuprofen: Oral Ibuprofen at 10 mg/kg dose
Eligibility criteria:
Inclusion Criteria:

ages 3-17 years old presenting to the pediatric ED
treating physician deems patient required ibuprofen Tylenol or both for pain relief

Exclusion Criteria:

documented or suspected pregnancy, (2)
parental refusal,
allergies to NSAIDS or APAP
inability to tolerate oral medications or contraindications to oral medication route
received analgesics within 4 hours prior to ED presentation
inability to use pain scales
Intervention: Bupivacaine
Trial phase: Phase 4
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 180
Group description: Aspirin and nerve pain medications including duloxetine and clonidine patch prior to surgery.
Combined Spinal Epidural with 1.5% Mepivacaine 4cc
A pain regimen while in the hospital that consists of Epidural PCA (EPCA) with 0.06% bupivacaine. Duloxetine (Cymbalta) - by mouth Ketorolac (Toradol) - IV Celecoxib (Celebrex) - by mouth Acetaminophen (Tylenol) - IV The EPCA will be removed when pain is well-controlled. Other medications, including opioids, will be available.
Acetaminophen and celecoxib for pain control once out of the hospital. Patients will also receive a prescription for an opioid medication in case they need it.

Bupivacaine: EPCA: Bupivacaine 0.06%.
Eligibility criteria:
Inclusion Criteria:

Any patient with osteoarthritis scheduled for primary total hip arthroplasty with a participating surgeon
Planned use of regional anesthesia
Planned posterolateral surgical approach
Age Range 45-80
Ability to follow study protocol

Exclusion Criteria:

Any patient with age <45 or >80
Any patient with planned anterior surgical approach
Any patient with prior major ipsilateral hip surgery
Any patient intending to receive general anesthesia
Any patient with an ASA of IV
Any patient with insulin-dependent diabetes
Any patient with hepatic (liver) failure (history of cirrhosis or elevated LFT's)
Any patient with chronic renal (kidney) failure (formal diagnosis of renal disease of elevated creatinine)
Any patient with history of gastric (stomach) ulcer
Chronic opioid use (taking opioids for >3 mo duration on a daily basis)
Chronic analgesic use (i.e. lyrica, gabapentin) for >3 mo duration
Stress dose steroids
Use of antidepressants
Contraindications to aspirin
Allergy to any of the medications (or adhesives) involved in the study protocol
Dementia
Non-English speakers.
Intervention: Physostigmine
Trial phase: Phase 4
ATC code: S01EB05 | V03AB19
SMILES: [H][C@]12N(C)CC[C@@]1(C)c1cc(OC(=O)NC)ccc1N2C
Sex: All
Age groups: Child
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 9
Group description: Physostigmine 0.02 mg/kg IV bolus (max of 2 mg), which can be repeated at 10 minutes, followed by a 0.02 mg/kg/hr (max of 2 mg/hr) infusion for 4 hours.

Physostigmine: Administration of physostigmine bolus followed by an infusion
Eligibility criteria:
Inclusion Criteria:

Age >=10 and < 18 years
Present to the Emergency Department or Intensive Care Unit for an antimuscarinic toxidrome from either a pharmaceutical agent such as antihistamine overdose, or natural toxins or products such as Datura stramonium
Antimuscarinic toxidrome will be defined with at least one central nervous system agitation effect (agitation, delirium, visual hallucinations, mumbling incomprehensible speech), and at least 2 peripheral nervous system adverse effect (mydriasis, dry mucus membranes, dry axillae, tachycardia, decreased bowel sounds).
Patients will also be required to have a RASS score of +2 to +4 on initial assessment.

Exclusion Criteria:

History of seizures or seizure during acute clinical course
History of asthma or wheezing during clinical course Bradycardia (Heart Rate <60)
Concomitant use of atropine or choline ester or depolarizing neuromuscular blocker during present illness and hospital course
Diabetes gangrene, known intestinal obstruction or urogenital tract, vagotonic state
QRS interval > 120 ms on electrocardiogram
Known to be pregnant at the time of enrollment
Known ward of the state
Intervention: Lorazepam
Trial phase: Phase 4
ATC code: N05BA06 | N05BA56
SMILES: O=C1Nc2ccc(Cl)cc2C(c2ccccc2Cl)=NC1O
Sex: All
Age groups: Child
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 10
Group description: Lorazepam 0.05 mg/kg IV bolus (max 2 mg), which can be repeated at 10 minutes if inadequate patient response, followed by a Normal Saline infusion for 4 hours.

Lorazepam: Administration of lorazepam bolus followed by normal saline infusion
Eligibility criteria:
Inclusion Criteria:

Age >=10 and < 18 years
Present to the Emergency Department or Intensive Care Unit for an antimuscarinic toxidrome from either a pharmaceutical agent such as antihistamine overdose, or natural toxins or products such as Datura stramonium
Antimuscarinic toxidrome will be defined with at least one central nervous system agitation effect (agitation, delirium, visual hallucinations, mumbling incomprehensible speech), and at least 2 peripheral nervous system adverse effect (mydriasis, dry mucus membranes, dry axillae, tachycardia, decreased bowel sounds).
Patients will also be required to have a RASS score of +2 to +4 on initial assessment.

Exclusion Criteria:

History of seizures or seizure during acute clinical course
History of asthma or wheezing during clinical course Bradycardia (Heart Rate <60)
Concomitant use of atropine or choline ester or depolarizing neuromuscular blocker during present illness and hospital course
Diabetes gangrene, known intestinal obstruction or urogenital tract, vagotonic state
QRS interval > 120 ms on electrocardiogram
Known to be pregnant at the time of enrollment
Known ward of the state
Intervention: Atomoxetine
Trial phase: Phase 2
ATC code: N06BA09
SMILES: CNCC[C@@H](Oc1ccccc1C)c1ccccc1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 10
Group description: Atomoxetine (40 mg qd titration dose for first seven days, followed by 80 mg qd target dose for remaining five weeks)
Eligibility criteria:
Inclusion Criteria:

Diagnosis of Multiple Sclerosis based on the Revised McDonald criteria
Age 21 - 60 years.
Patient self-report of memory decline from previously higher level of functioning.

Memory Impairment on validated neuropsychological memory screening tests, as follows:

performance ≤16th percentile on both (i) Rey Auditory Verbal Learning Test (RAVLT) Total Learning (TL) and (ii) WMS-IV Visual Reproduction I (VR-I); and b) mean normative memory performance (RAVLT TL and WMS-IV VR-I) is at least 1.0 standard deviation below expectations based on the Wechsler Test of Adult Reading (WTAR)

Exclusion Criteria:

Current stimulant medication usage.
Previous diagnosis or treatment for ADHD or any neurologic condition other than multiple sclerosis (e.g., traumatic brain injury, epilepsy)
Clinical relapse of MS within 60 days of screening,
Change in disease-modifying therapy within 90 days of screening,
Below average estimated premorbid intelligence (WTAR, < 16th percentile),
Severe cognitive impairment indicated by a Mini-Mental Status Examination (MMSE) < 24/30.
Contraindications for atomoxetine use: (a) self-reported history of suicidal ideation within the last twelve months (Columbia Suicide Severity Rating Scale), (b) diagnosis of bipolar illness, (c) moderate or severe current depressive symptomatology (Beck Depression Inventory Fast Screen ≥ 9), (d) diagnosis of hepatic disease, (e) narrow angle glaucoma, (f) pheochromocytoma, (g) monoamine oxidase inhibitor within 14 days of study drug start, (h) taking strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine, quinidine), (i) diagnosis of heart disease, (j) pregnant or planning pregnancy during the study period, (k) breastfeeding, (l) hypersensitivity to atomoxetine or component of formulation.
Intervention: Ramelteon
Trial phase: Phase 4
ATC code: N05CH02
SMILES: CCC(=O)NCC[C@@H]1CCc2ccc3c(c21)CCO3
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: Patients given ramelteon and re-evaluated after 15 days of therapy

Ramelteon Pill: Patients with compensated cirrhosis and insomnia will be provided ramelteon
Eligibility criteria:
Inclusion Criteria:

Child class A cirrhosis proven by biopsy, radiology or endoscopic evidence of varices - Able to give informed consent

Exclusion Criteria:

Patient unwilling to start therapy
Allergic reactions to ramelteon in the past
Obstructive sleep apnea
Periodic limb movement disorder
Moderate to severe depression
Unable to give informed consent
Night shift workers
Inter-continental travel within the last 4 weeks
Renal insufficiency on dialysis
Current alcohol or illicit drug use
Diabetes Mellitus using insulin therapy
Use of chronic hypnotic medications more than once per week or more than 5-6 times per month
Intervention: Metronidazole
Trial phase: Phase 3
ATC code: A01AB17 | A02BD01 | A02BD02 | A02BD03 | A02BD08 | A02BD11 | A02BD13 | A02BD15 | D06BX01 | G01AF01 | G01AF20 | J01RA03 | J01RA04 | J01RA10 | J01RA14 | J01XD01 | P01AB01 | P01AB51 | P01AB52
SMILES: Cc1ncc([N+](=O)[O-])n1CCO
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 285
Group description: Metronidazole Vaginal Gel, 0.75% applied vaginally as directed.

Metronidazole Vaginal Gel 0.75%: Metronidazole Vaginal Gel 0.75% is an FDA-approved drug
Eligibility criteria:
Inclusion Criteria:

Non-pregnant female aged ≥ 18 years who is in good general health
Diagnosis of BV
Willing to refrain from using any intravaginal product (e.g., spermicide, tampon, douche, feminine deodorant spray, diaphragm, vaginal ring birth control, or condom with spermicide or insertion into the vagina of any drug or non-drug product during treatment), other than study treatment for the duration of the trial
Subjects of childbearing potential who have a negative urine pregnancy test at the Entry Visit (Visit 1) and agree to use an acceptable form of birth control throughout the study
Able to understand and willing to sign the informed consent form (ICF) and able to comply with the requirements of the protocol

Exclusion Criteria:

History of alcohol or substance abuse
Experienced a clinically significant medical event within 90 days
Abnormal pap or high risk human papillomavirus (HPV)
History or presence of clinically significant central nervous system (CNS), cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, gynecologic, dermatologic, neurologic, oncologic, or psychiatric disease
Pregnant, lactating, or planning to become pregnant or breastfeed during the study period
Primary or secondary immunodeficiency
Evidence of any vulvovaginitis at screening other than BV
History of hypersensitivity or allergy to metronidazole, parabens, other nitroimidazole derivatives, or other ingredients of the GDC 229 (metronidazole 0.75% vaginal gel), metronidazole 0.75% vaginal gel (Oceanside Pharmaceuticals), or vehicle gel
Participating in another clinical trial
Intervention: 575OB1Ckn0
Trial phase: Phase 2
SMILES: CC(C)NC(=O)Cn1c(-c2cccc(Cl)c2)nn(-c2ccc(CCN3CCOCC3)cc2)c1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 16
Group description: TS-121 10 mg: Orally taken once daily
Eligibility criteria:
Inclusion Criteria:

Adult males and females between 18 and 65 years of age inclusive (at time of initial informed consent)
Patients with a current diagnosis of MDD by DSM-5, confirmed through a structured interview using MINI
Patients who receive the same antidepressant (SSRI, SNRI or bupropion monotherapy) for at least 6 weeks of continuous treatment with at least 4 weeks on a fixed dose
Patients who willing to remain on the same primary SSRI, SNRI or bupropion and fixed dose throughout the course of the study

Patients who meet the total score on the HAM-D as listed below

HAM-D ≥ 18 at Screening
HAM-D ≥ 18 at Baseline
Body Mass Index (BMI) ≥ 18 and ≤ 38 kg/m2

Exclusion Criteria:

Patients with inadequate response to ≥2 prior antidepressant treatments (not including current antidepressant) of at least 4 weeks duration each for the current episode
Patients whose current depressive episode is diagnosed with psychotic features, catatonic features, post-partum (primary onset), or is secondary to a general medical disorder

Patients with a diagnosis of any of the following DSM-5 class disorders

Schizophrenia spectrum and other psychotic disorders
Bipolar and related disorders
Anxiety disorders [Co-morbid GAD and SAD will be allowed in the study if the primary diagnosis is MDD, and if in the opinion of the investigator, the comorbid anxiety is not likely to interfere with the subject's ability to participate in the trial or affect study outcome]
Obsessive-compulsive and related disorders
Trauma- and Stressor-related disorders
Patients who received electroconvulsive therapy (ECT) within 12 months of Screening, received more than one course of ECT in their lifetime or plan to receive ECT during the study
Patients who received repetitive transcranial magnetic stimulation (rTMS) within 12 months of Screening or plan to receive rTMS during the study
Patients who plan to initiate or terminate cognitive or behavioral psychotherapy or alter the frequency of ongoing therapy during this study
Patients who have attempted suicide within the past 6 months
Patients with history or presence of intellectual disability, pervasive developmental disorder, cognitive disorder, neurodegenerative disorder, or brain injury
Patients with any history or complication of convulsive disorder
Patients who are undergoing treatment with psychotropic medications, benzodiazepines, metyrapone, lithium and/or corticosteroids
Patients who are taking moderate to strong CYP3A4 inhibitors/inducers
Intervention: ASPIRIN
Trial phase: Phase 2 | Phase 3
ATC code: A01AD05 | B01AC06 | B01AC56 | C07FX02 | C07FX03 | C07FX04 | C10BX01 | C10BX02 | C10BX04 | C10BX05 | C10BX06 | C10BX08 | C10BX12 | M01BA03 | N02AJ02 | N02AJ07 | N02AJ18 | N02BA01 | N02BA51 | N02BA71
SMILES: CC(=O)Oc1ccccc1C(=O)O
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 17
Group description: In this group (n = 17), patients received 3 g of omega-3 polyunsaturated fatty acids plus 100 mg of aspirin daily supplementation over a period of 180 days and open flap debridement was performed to treat residual pockets.

Open flap debridement: Open flap debridement was performed to decontaminate root surface

Omega-3 polyunsaturated fatty acids: 3 g of omega-3 polyunsaturated fatty acids daily supplementation over a period of 180 days

Aspirin: 100 mg of aspirin daily supplementation over a period of 180 days
Eligibility criteria:
Inclusion criteria

Diagnosis of generalized aggressive periodontitis (Armitage, 1999; American Academy of Periodontology, 2015);
Have undergone a first approach for periodontal treatment (full-mouth ultrasonic debridement);
Present at least one residual pocket of probing depth ≥ 5 mm and bleeding on probe not located in furcation region;
Good general health;
Agree to participate in the study and sign the informed consent form (TCLE) after explaining the risks and benefits;

Exclusion Criteria

Systemic problems (cardiovascular alterations, blood dyscrasias, immunodeficiency - ASA III / IV / V) that contraindicate the periodontal procedure;
Have used antibiotics and anti-inflammatories in the last six months;
Smoke ≥ 10 cigarettes/day;
Pregnant or nursing;
Chronic use of medications that may alter the response of periodontal tissues;
Indication of antibiotic prophylaxis for dental procedures;
History of allergic reaction to acetylsalicylic acid, fish or seafood.
Intervention: ASPIRIN
Trial phase: Phase 2 | Phase 3
ATC code: A01AD05 | B01AC06 | B01AC56 | C07FX02 | C07FX03 | C07FX04 | C10BX01 | C10BX02 | C10BX04 | C10BX05 | C10BX06 | C10BX08 | C10BX12 | M01BA03 | N02AJ02 | N02AJ07 | N02AJ18 | N02BA01 | N02BA51 | N02BA71
SMILES: CC(=O)Oc1ccccc1C(=O)O
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 38
Group description: In this group (n = 19), patients will take 900 mg of omega-3 polyunsaturated fatty acids and 100 mg of aspirin daily over a period of 180 days and full-mouth ultrasonic debridement was performed to treat diseased sites.
Eligibility criteria:
Inclusion Criteria:

diagnosis of GAgP (AAP, 1999);
presence of ≥20 teeth;
presence of ≥ 6 sites presenting PD ≥ 5mm with bleeding on probing (BOP) and ≥2 sites with PD ≥7mm (including incisors and first molars, in addition to other two non-contiguous teeth);
good general health;
agree to participate in the study and sign a written informed consent. All subjects will be individually informed about the objectives, probable risks and benefits of the protocol treatment (according to Resolution nº196 of October 1996 and to the Professional Code of Dental Ethics - 179/93).

Exclusion Criteria:

pregnancy or lactating;
suffer from any systemic disease (e.g. cardiovascular disorders, diabetes, blood dyscrasias, immunodeficiency, etc) which could alter the course of periodontal disease;
took antimicrobials in the previous 6 months;
taking long-term anti-inflammatory drugs;
previous periodontal treatment within the last 12 months;
smoker ≥ 10 cigarettes.
Intervention: Zepatier
Trial phase: Phase 4
ATC code: J05AP54
SMILES: C=CC1CC1(NC(=O)C1CC2CN1C(=O)C(C(C)(C)C)NC(=O)OC1CC1CCCCCc1nc3ccc(OC)cc3nc1O2)C(=O)NS(=O)(=O)C1CC1.COC(=O)NC(C(=O)N1CCCC1c1ncc(-c2ccc3c(c2)cc2n3C(c3ccccc3)Oc3cc(C4=NC(C5CCCN5C(=O)C(NC(=O)OC)C(C)C)N=C4)ccc3-2)[nH]1)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 25
Group description: 25 People Who Inject Drugs engaged in a Medication Assisted Therapy treatment program for their substance use disorder, treated for their HCV using elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.

elbasvir-grazoprevir (50 mg/100 mg): 12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)
Eligibility criteria:
Inclusion Criteria:

Genotype 1b and genotype 1a without baseline NS5A resistance or Genotype 4
APRI Score <0.7; if >0.7 a Fibrosure/Fibrotest or Fibroscan score of F2 or less
No clinical or laboratory evidence of cirrhosis
Readiness for treatment based on ability to make >2/3 sequential office visits
Patients must be assessed to have decision-making capacity, be capable of consenting, and not be displaying evidence of overt intoxication.

Exclusion Criteria:

Clinical or Laboratory Evidence of Cirrhosis
Elevated prothrombin time unrelated to anticoagulation, hemoglobin level less than 12.3 g/L in females and <14 g/L in males, platelet count <150 × 109 cells/L), white blood cells (WBC) <4.0 x103/mm3 , aminotransferase levels more than 10 times the upper limit of normal, or albumin level <3.5 g/L.
Previous treatment for hepatitis C infection
Hepatocellular carcinoma
HIV or hepatitis B virus co-infection
Subjects taking medications that are contra-indicated to administer with Zepatier including phenytoin, carbamazepine, rifampin, St. John's Wort, and cyclosporine AND unable to change these medications to one without interactions.